FindTrial
Sign In

Levels of posaconazole medicine seen in blood when different brands are used in patients with blood-related cancers taking this drug to prevent severe fungal infections

Plasma concentrations of generic posaconazole tablets used as Prophylaxis against invasive fungal infections: A prospective study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/07/113622
Enrollment
50
Registered
2026-07-07
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C81-C96- Malignant neoplasms of lymphoid, hematopoietic and related tissue Health Condition 2: B49- Unspecified mycosis

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Amrita Vishwa Vidyapeetham
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients admitted under hematology taking posaconazole for prophylaxis against invasive fungal infections Giving written informed consent and assent for the age group 12 to 14 years

Exclusion criteria

Exclusion criteria: Nil

Design outcomes

Primary

MeasureTime frame
Plasma concentrations of posaconazoleTimepoint: Levels will be measured at 5 days to 1 week initially and repeated at 28 to 30 days—

Secondary

MeasureTime frame
Incidence of invasive fungal infectionsTimepoint: over the period of 1 year from the date of enrolment—

Countries

India

Contacts

Public ContactLaxmi Govindraj

Amrita School of Medicine

laxmig@aims.amrita.edu9446825445

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026